Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Bloomberg Portfolio Manager sees small company acquisitions
View:
Post by Noteable on Jun 15, 2023 6:58pm

Bloomberg Portfolio Manager sees small company acquisitions

June 15, 2023 - Bloomberg's " Portfolio Manager expects that the overweighting of small and mid cap companies will deliver positive results to shareholders. In particular, they expect that the divergence in the valuations of large and small/mid cap companies will close. In addition, they anticipate that we can expect to see continued consolidation in the biotechnology industry, as larger companies seek to acquire smaller companies with promising pipelines of drugs and therapies to address gaps in their own portfolios and, in many cases, impending patent expirations which threaten their future earnings. This consolidation is likely to create both opportunities and challenges for small biotechnology companies, as they navigate the changing landscape of the industry.

https://www.bloomberg.com/press-releases/2023-06-15/the-biotech-growth-trust-plc-annual-financial-report

 "The biotechnology sector has been a critical area of innovation and growth in recent years with the rate of underlying scientific discovery and its translation into effective treatments continuing apace. With a focus on precision medicine, cell and gene therapy, digital health, and rare diseases, small biotechnology companies are at the forefront of this innovation. Additionally, advances in technology, the availability of big data and the use of artificial intelligence are enabling healthcare solutions which have the potential to revolutionise the industry."  - Roger Yates Chairman
Comment by westcoast1000 on Jun 15, 2023 7:41pm
Thanks, Noteable. And NO, this piece from bloomberg was NOT paid for by ONCY, although it seems to apply directly to us.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities